Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

Study Identifier
GMA-US-OAB-0403
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
  • Study Drug
  • onabotulinumtoxinA
  • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary retention.

    Study Locations

    Location
    Status
    Location
    University of California, Davis
    Davis, California, United States, 95616
    Status
    Not applicable
    Location
    Capital Region Urology
    Irvine, California, United States, 92612
    Status
    Not applicable
    Location
    The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System
    Charlotte, North Carolina, United States, 28203
    Status
    Not applicable
    Location
    Alliance Urology Specialists, PA
    Greensboro, North Carolina, United States, 27403
    Status
    Not applicable
    Location
    Forsyth Memorial Hospital Inc. dba Novant Health Urology Partners
    Winston-Salem, North Carolina, United States, 27103
    Status
    Not applicable
    Location
    MetroHealth Medical Center
    Cleveland, Ohio, United States, 44109
    Status
    Not applicable
    Showing {first} - {last} of {total} Results